Review about Luspatercept. Health, Medicine, Nursing Term Paper

Luspatercept Review
Name:
Institution Affiliation:
Course:
Professor’s Name:
Date:
Luspatercept Review
Lower-risk myelodysplastic syndrome (MDSs) anaemia and primary myelofibrosis (PMF) become resistant to existing medicine, causing transfusion of red blood cells (RBC). This also causes shortened survival, iron overload, and poor quality life. The growth factor causing the transformation is expressed in MDSs and PMF of lower-risks (Piga, 2015). Luspatercept ligand traps that inhibit growth differentiation factors (GDFs) 11 helps in transfusion independence of lower-risk MDSs to available treatments of 10 to 50 percent. MDS lower-risk anaemia symptoms can be treated by transfusion of red blood cells or treatments that increase the level of haemoglobin. Patients getting RBC transfusions to experience chronic anaemia and have average haemoglobin, Hb<9 g/dL. Luspatercept has also been found to be effective for dealing with b-thalassemia, a blood disorder that reduces hemoglobin production and thus low oxygen levels in a patient’s body. B-thalassemia is an inherited disease which caused by beta-globin gene mutations which undermine the the beta-globin chain synthesis process in the body (Weatherall & Clegg, 2008).
Existing Treatments
Glycosylated (darbepoetin) and recombinant erythropoietin (EPO) forms are the preferred treatments for lower-risk anaemia. However, the drugs are not considered in MDS that have isolated del 5q. Lenalidomide results in better response of erythroid in this case. In a study, it is observed that in 18-24 months, EPO and darbepoetin have no impact on the progression of AML. Instead, they lead to improved survival depicting that maintaining an average haemoglobin level and avoiding overload of iron reduces deaths resulting from nonleukemic causes. Patients with low-level EPO baseline respond better to darbepoetin and erythropoietin drugs. They also showed non-requirement of RBC transfusion and fewer mutations of somatic. Patients who respond well to EPO and darbepoetin usually relapse without progression to higher risks. When the two drugs fail, adding of a colony-stimulating factor-like granulocyte induces 20 to 30 percent responses (Platzbecker et al., 2015). When del (5q) is not present, lenalidomide generates 25 percent TI rates. When combined with both EPO and darbepoetin, it yields a rate of 40 percent. 30 to 50 percent responses reported in a median duration when hypomethylating agents (HMAs) are used. Antihymocyte globin yields 30 to 40 percent erythroid response from lower-risk patients. This suggests that when patients are resistant to EPO and darbepoetin, their treatment options are limited. Fortunately, new medications are being proposed for them. Among the proposed is luspatercept a transforming growth factor (TGF) family that was approved by the FDA. This is one of the effective mitigations for MDS-RS. Moreover, the Food and Drug Administration (FDA) on November 8, 2019 approved the use of luspatercept-aamt (REBLOZYL, Celgene Corp.) to treat anemia in adult patients patients suffering form b-thalassemia and requiring red blood cell transfusions on a regular basis U.S. FDA. (2019). 
How TGFs Work
These type of drugs include activins, bone morphogenetic...